Eli Lilly and Company has significantly expanded its oncology portfolio with the definitive agreement to acquire Ajax Therapeutics, a clinical-stage…
Read More
Lilly Emerges as Top Pharma Company by Revenue in FY2025, Fueled by Mounjaro and Zepbound’s $36.5 Billion Success
Eli Lilly and Company has officially concluded its fiscal year 2025 as the world’s leading pharmaceutical enterprise by revenue, a…
Read More
A Billion-Dollar Telehealth Empire Built on Regulatory Cracks: The Medvi Controversy
Medvi, a telehealth company recently profiled by The New York Times as an AI-powered success story, is projected by its…
Read More
AbbVie Invests $1.4 Billion in North Carolina for New Manufacturing Hub
AbbVie, a global biopharmaceutical leader, has announced a landmark $1.4 billion investment to establish its first manufacturing facility in North…
Read More
Insilico CEO sees potentially $2.75 billion collaboration as ‘fusing Lilly’s clinical excellence’ with Insilico’s ‘end-to-end AI engine’
Insilico Medicine, a pioneering company in artificial intelligence-driven drug discovery and development, has cemented a landmark global research and development…
Read More
Eli Lilly Expands In Vivo Gene Therapy Arsenal with $7 Billion Acquisition of Kelonia Therapeutics
Eli Lilly and Company has significantly bolstered its position in the rapidly evolving cell and gene therapy (CGT) landscape with…
Read More
UCB Acquires Neurona Therapeutics for Up to $1.15 Billion to Bolster Epilepsy Pipeline with Regenerative Cell Therapy
BRUSSELS, BELGIUM & SAN FRANCISCO, USA – April 20, 2026 – Global biopharmaceutical leader UCB has finalized a definitive agreement…
Read More
Chinese firms landed 6 of 26 major pharma deals in 16 months, worth $53 billion
Over the past 16 months, Chinese-domiciled biotechnology companies have emerged as formidable forces in the global pharmaceutical landscape, featuring prominently…
Read More
The Non-GLP-1 Obesity Drug Market Set for Explosive 50-Fold Growth, Reaching $15.5 Billion by 2031
The global pharmaceutical market for obesity treatments is poised for a dramatic transformation, with a burgeoning segment of non-Glucagon-like peptide-1…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company, a pharmaceutical giant currently experiencing unprecedented growth driven by its blockbuster GLP-1 agonists, has announced an…
Read MoreYOU MAY HAVE MISSED
